profit from every $100 of sales.
$0$100
BioLife Solutions
We have no price for BioLife Solutions since 7 October 2026. It may have been taken over, merged or renamed, so the figures below are from then.
$38.61+0.00% today
+40.7% in 1 year
1-year low $18.151-year high $39.22
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What BioLife Solutions sold, what it kept, and what it did with the cash.
Sales went from $76.2 million in 2022 to $96.2 million in 2025, with -$4.60 million of profit last year.
SalesProfit
BioLife Solutions vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| BioLife Solutions | No profit yet | ||
 ResMed | 22.1× · Fair price | ||
 West Pharmaceutical Services | 58.0× · Expensive | ||
 Hologic | 30.0× · Fair price | ||
 Baxter International | No profit yet |
AI analysis
An AI analyst reads BioLife Solutions's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 76 | 68 | 75 | 96 | |
| 47 | 41 | 50 | 62 | |
| -11 | -19 | -4 | -17 | |
| 6 | -7 | 4 | -12 | |
| -140 | -68 | -20 | -5 | |
| -3.29 | -1.55 | -0.44 | -0.10 | |
| 61.5% | 60.7% | 67.1% | 64.6% | |
| -14.0% | -28.5% | -6.0% | -17.3% | |
| -183.4% | -100.0% | -27.0% | -4.8% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 450 | 413 | 399 | 406 |
| Cash | 19 | 28 | 92 | 33 |
| Total debt | 44 | 34 | 30 | 18 |
| Total liabilities | 86 | 75 | 51 | 34 |
| 364 | 338 | 349 | 372 | |
| 42 | 44 | 46 | 49 | |
| -2.1% | -4.1% | -0.9% | -3.4% | |
| -38.4% | -20.1% | -5.8% | -1.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -8 | -12 | 8 | 20 | |
| 10 | 6 | 4 | 20 | |
| -19 | -19 | 5 | 0 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 25 | 33 | 31 | 23 |
Valuation
- –
- 261.3×
- –
- 3.2×
- 19.6×
- 4,540.7×
- –
- 0.0%
- -0.2%
- 0.0%
Profitability
- 64.6%
- -17.3%
- -4.8%
- -7.5%
- -2.8%
- -12.5%
- -2.9%
- -2.6%
- -2.8%
- 8.2%
Growth
- +8.1%
- –
- +104.4%
- –
- +5.5%
Financial health
- -1.3×
- 0.04
- 3.7%
- -16.5×
- 7.30
- 5.50
- 0.25
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 32%of 952
Bottom 12%of 883
Bottom 39%of 870
Bottom 40%of 985
What analysts expect
- Average price target
- $33.00
- Range
- $32.00 – $34.00
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 0.04 | 0.01 | +300.0% |
| Feb 26, 2026 | 0.04 | -0.02 | +300.0% |
| Nov 6, 2025 | 0.04 | 0.00 | +1,900.0% |
| Aug 7, 2025 | -0.33 | -0.03 | −888.5% |
| May 8, 2025 | 0.04 | -0.05 | +182.4% |
| Mar 3, 2025 | -0.01 | -0.06 | +83.3% |
| Nov 12, 2024 | -0.02 | -0.08 | +74.5% |
| Aug 8, 2024 | -0.06 | -0.14 | +56.6% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
26No pass
Benjamin Graham
40No pass
Philip Fisher
32No pass
Peter Lynch
42No pass
Joel Greenblatt
0No pass
Charlie Munger
31No pass
Terry Smith
27No pass
Questions about BioLife Solutions
Is BioLife Solutions a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the BioLife Solutions AI analysis
What does BioLife Solutions do?
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. It is in Medical - Instruments & Supplies.
Does BioLife Solutions pay a dividend?
No. BioLife Solutions does not pay a dividend at the moment.
Is BioLife Solutions stock halal?
Yes. BioLife Solutions passes our halal screen: its business is permitted and its debt is 0.9% of its market value, under the 30% limit. How we check
How has BioLife Solutions stock done over the past year?
Up 40.7% over the past twelve months, to $38.61. It traded between $18.15 and $39.22, close to its high.
Who are BioLife Solutions's competitors?
The largest listed companies in the same industry are ResMed, West Pharmaceutical Services, Hologic and Baxter International. The peers table on this page compares their profit, growth and price with BioLife Solutions's.
Prices: daily closes to Oct 7, 2026. Fundamentals: company reports via invest-like data.